NUWE · Nuwellis, Inc. · Exempt Offerings
$0.69
-0.06 (-7.37%)
At close · Oct 2
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions, including continued operating losses, negative cash flows from operations, an accumulated deficit of $325.7 million, and the need for additional capital to fund ongoing operations and growth initiatives (including the integration of Rendiatech Ltd., and Israeli company ("Rendiatech") following the Company's acquisition), raise substantial doubt about the Company's ability to continue as a going concern for at least twelve months from the date these financial statements are issued. ... While management's plans, including recent financing activities, cost discipline initiatives, and contingency measures, are intended to address these conditions, such plans do not alleviate the substantial doubt.”View the 10-Q filed Aug 13, 2026
Market Cap
$2.83M
Shares
3.65M
Volume · Oct 2
108.5K
Avg daily vol (3M)
4.34M
Private capital raises reported to the SEC on Form D under Regulation D, showing the offering size, amount sold, minimum investment and number of investors. Public operating companies rarely raise capital this way, so this page is often empty.
| Filed | Type | Industry | Offering | Sold | Exemptions |
|---|---|---|---|---|---|
| 2024-11-20 | New | Other Health Care | $3,848,286 | $3,848,286 | 06b |
| 2024-09-04 | New | Other Health Care | Indefinite | $0 | 06b |
| 2024-08-02 | New | Other Health Care | Indefinite | $0 | 06b |
| 2023-06-26 | New | Biotechnology | Indefinite | $0 | 06b |
| 2020-05-07 | New | Biotechnology | $1,699,998 | $1,699,998 | 06b |
| 2020-04-08 | New | Biotechnology | $2,226,519 | $2,226,519 | 06b |
| 2020-03-30 | New | Biotechnology | $1,248,418 | $1,248,418 | 06b |
Showing 1–7 of 7 filings